Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 14/20 | 0.79 |
| ▸ | IKBKB | O14920 | 4/20 | 0.70 |
| ▸ | CHUK | O15111 | 4/20 | 0.70 |
| ▸ | AKT1 | P31749 | 4/20 | 0.70 |
| ▸ | AKT2 | P31751 | 4/20 | 0.70 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.70 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481544 | 1.00 | PADI4 (0.79) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23511031 | 0.98 | PADI4 (0.76) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6059498 | 0.97 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6059500 | 0.97 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6493833 | 0.94 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6493835 | 0.94 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23510889 | 0.94 | PADI4 (0.74) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6495731 | 0.94 | PADI4 (0.79) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6491632 | 0.94 | PADI4 (0.74) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23511044 | 0.94 | PADI4 (0.78) | PADI4IKBKBCHUKAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | claimed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | PADI4 1762/4885IKBKB 693/4885CHUK 126/4885 |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | EIF4E, EIF4A1, EIF4A2 | PADI4 4191/4885IKBKB 1115/4885CHUK 724/4885 |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885IKBKB 1218/4885CHUK 923/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | PADI4 4191/4885IKBKB 1115/4885CHUK 724/4885 |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP2 | PADI4 1662/4885IKBKB 2485/4885CHUK 723/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885IKBKB 1218/4885CHUK 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.